Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amur Minerals ( (GB:CRTX) ) just unveiled an update.
CRISM Therapeutics Corporation has submitted a Clinical Trial Authorisation application to the UK MHRA for a Phase 2 clinical study of its ChemoSeed technology in treating glioblastoma. This trial aims to assess the safety and efficacy of localized irinotecan delivery directly into the resection margin post-surgery, potentially improving outcomes over conventional chemotherapy. The trial is structured in two parts, with the first focusing on dose escalation in recurrent glioblastoma and the second on a larger patient group, including both newly diagnosed and recurrent cases. The primary endpoint is progression-free survival, with the trial expected to start in 2026 and report results by 2029.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based company specializing in innovative drug delivery technologies aimed at enhancing the effectiveness of cancer treatments for solid tumors. Their flagship product, ChemoSeed, is designed for localized chemotherapy delivery, particularly beneficial in treating high-grade gliomas by bypassing the blood-brain barrier.
Average Trading Volume: 81,125
Technical Sentiment Signal: Strong Buy
Current Market Cap: £1.83M
For a thorough assessment of CRTX stock, go to TipRanks’ Stock Analysis page.